How Neuroinflammation Works

The brain's resident immune cells, called microglia, extend and retract tiny processes up to a hundred times per hour, surveying their assigned territories like sentries on patrol. These cellular guardians possess specialized receptors that recognize "danger-associated molecular patterns"—molecular fragments released when neurons die, proteins misfold, or pathogens invade. When a microglial process encounters ATP leaking from damaged cells, misfolded proteins like amyloid-beta, or bacterial components, these receptors bind to the threat molecules and transmit alarm signals into the cell's interior.

Neurons themselves broadcast distress through "find-me" and "eat-me" signals when injured or dying. A struggling neuron might release fractalkine, a protein that specifically activates microglia, or display phosphatidylserine on its outer membrane—a lipid normally hidden inside healthy cells. Astrocytes, the star-shaped support cells of the brain, also participate in detection by sensing glutamate spillover from damaged synapses or detecting changes in potassium levels that indicate neuronal distress.

This detection system operates with remarkable sensitivity because the brain cannot afford to ignore threats—yet it must also avoid false alarms that could damage healthy tissue. The variety of receptors involved, from toll-like receptors to purinergic sensors, ensures the brain can distinguish between different types of danger and mount appropriately calibrated responses.

Once danger signals trigger microglial receptors, these cells undergo a dramatic morphological transformation. Their delicate, extensively branched processes retract, and the cell body swells and rounds, adopting an amoeboid shape optimized for movement and phagocytosis rather than surveillance. This shape-shifting occurs as the cellular skeleton reorganizes—actin filaments rearrange, and the microglia reprograms which genes it expresses, ramping up production of immune molecules while downregulating housekeeping functions.

The activation process follows a spectrum rather than a simple on-off switch. Researchers once categorized activated microglia as either "M1" (pro-inflammatory) or "M2" (anti-inflammatory), but it's now clear that microglia adopt mixed phenotypes depending on the specific signals they receive. A microglial cell responding to bacterial infection will activate differently than one encountering a dying neuron, expressing distinct combinations of surface markers and secreting different molecular cocktails.

Astrocytes undergo their own activation, becoming "reactive astrocytes" that enlarge, proliferate, and alter their molecular profiles. Their normally fine processes thicken, and they begin producing immune signaling molecules they wouldn't make in their resting state. This reactive transformation can be triggered directly by damage or indirectly by signals released from activated microglia, creating a coordinated immune response across different cell types.

Activated microglia and astrocytes become molecular factories, synthesizing and secreting dozens of signaling proteins called cytokines and chemokines. Pro-inflammatory cytokines like interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha flood the local environment, amplifying the immune response and altering neuronal function. These molecules can change how neurons fire, how synapses transmit signals, and how other brain cells respond—essentially reprogramming the tissue's behavior to prioritize defense over normal function.

Beyond proteins, activated immune cells release reactive oxygen species and reactive nitrogen species—chemically aggressive molecules containing oxygen or nitrogen atoms with unpaired electrons. While these free radicals help destroy pathogens and break down cellular debris, they also oxidize lipids in cell membranes, damage DNA, and modify proteins in ways that can impair their function. The brain is particularly vulnerable to oxidative damage because of its high metabolic rate and abundant lipid content.

Some released molecules serve protective purposes: growth factors like brain-derived neurotrophic factor support neuronal survival, while anti-inflammatory cytokines like interleukin-10 attempt to restrain the immune response. The balance between these pro- and anti-inflammatory mediators determines whether inflammation resolves safely or spirals into tissue damage. In acute neuroinflammation following a stroke, this molecular release helps clear debris and initiate repair, but the same mechanisms become destructive when chronically activated.

The blood-brain barrier normally functions as a highly selective border, with endothelial cells joined by tight junction proteins that prevent most blood-borne substances from entering the brain. During neuroinflammation, cytokines like tumor necrosis factor-alpha and interleukin-1 beta directly affect these endothelial cells, causing them to modify their tight junction proteins. The molecular seals between cells loosen, increasing permeability and allowing plasma proteins, ions, and even whole cells to cross from blood into brain tissue.

This barrier breakdown creates a two-way street for trouble. Water and plasma proteins leak into the brain, causing edema that can increase intracranial pressure and compress delicate neural tissue. Simultaneously, inflammatory signals from inside the brain reach the bloodstream, and endothelial cells respond by expressing adhesion molecules on their luminal surface—molecular "velcro" that catches circulating immune cells. Neutrophils, monocytes, and T-cells rolling through brain capillaries stick to this activated endothelium, squeeze between endothelial cells, and enter the brain parenchyma.

Once peripheral immune cells infiltrate, they often intensify inflammation beyond what resident microglia alone could produce. Neutrophils release proteases and oxidants that can damage the extracellular matrix and myelin sheaths. Infiltrating monocytes differentiate into macrophages that are often more inflammatory than resident microglia. In autoimmune conditions like multiple sclerosis, T-cells that have been primed against brain antigens cross this compromised barrier and attack oligodendrocytes, the cells that make myelin.

Neuroinflammation can spiral into a self-sustaining cycle when the molecules released during the initial response trigger additional rounds of activation. Cytokines secreted by microglia activate astrocytes, which release their own cytokines that further stimulate microglia, creating a positive feedback loop. Damaged neurons release danger signals that activate more microglia, but the inflammatory environment created by those microglia stresses additional neurons, causing them to die and release more danger signals—a vicious circle that persists long after the initial insult.

Chronic activation fundamentally changes microglial identity through a process called "priming." Primed microglia become hyperreactive, responding more aggressively to subsequent stimuli than they would have initially. This heightened sensitivity occurs partly because inflammatory signaling modifies gene expression patterns through epigenetic changes—chemical modifications to DNA and histones that persist over time. In aged brains or after repeated inflammatory insults, microglia can remain primed indefinitely, contributing to neurodegenerative diseases.

The amplification process also involves the breakdown of normal regulatory mechanisms. Anti-inflammatory signals that would typically resolve acute inflammation become less effective—microglia may downregulate receptors for inhibitory molecules or produce enzymes that degrade anti-inflammatory mediators. Dysfunctional mitochondria in chronically activated microglia produce excessive reactive oxygen species while generating less energy, and these damaged mitochondria themselves become sources of danger signals, further feeding the inflammatory fire.

This chronic state characterizes many neurodegenerative diseases. In Alzheimer's disease, microglia initially attempt to clear amyloid plaques but become chronically activated around these protein deposits, releasing inflammatory mediators that damage nearby neurons. In Parkinson's disease, activated microglia surround dying dopamine neurons in the substantia nigra, contributing to progressive cell loss. Breaking these amplification cycles has become a major target for therapeutic development.